Phase 1 Study of MPC-3100 in Patients With Refractory or Relapsed Cancer.

Trial Profile

Phase 1 Study of MPC-3100 in Patients With Refractory or Relapsed Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2011

At a glance

  • Drugs MPC 3100 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Myrexis media release.
    • 09 Nov 2011 Final results are expected before the end of November 2011, according to a Myrexis media release.
    • 08 Sep 2011 Status changed from active, no longer recruiting to completed, as reported in a Myrexis media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top